Compare CFFI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFI | TLSI |
|---|---|---|
| Founded | 1927 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.2M | 270.2M |
| IPO Year | 1996 | N/A |
| Metric | CFFI | TLSI |
|---|---|---|
| Price | $77.60 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 5.7K | ★ 448.5K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ 37.94 | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $140,841,000.00 | N/A |
| Revenue This Year | N/A | $35.45 |
| Revenue Next Year | N/A | $37.58 |
| P/E Ratio | $37.02 | ★ N/A |
| Revenue Growth | ★ 10.63 | N/A |
| 52 Week Low | $61.45 | $2.20 |
| 52 Week High | $86.18 | $7.95 |
| Indicator | CFFI | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 50.15 |
| Support Level | $68.17 | $3.69 |
| Resistance Level | $78.93 | $4.38 |
| Average True Range (ATR) | 2.49 | 0.34 |
| MACD | -0.64 | -0.05 |
| Stochastic Oscillator | 11.82 | 33.06 |
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.